<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">HJBM</journal-id><journal-title-group><journal-title>Hans Journal of Biomedicine</journal-title></journal-title-group><issn pub-type="epub">2161-8976</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/HJBM.2019.93019</article-id><article-id pub-id-type="publisher-id">HJBM-31260</article-id><article-categories><subj-group subj-group-type="heading"><subject>HJBM20190300000_52236485.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  microRNA-29a对肥大心肌细胞细胞周期的影响研究
   Study of miR-29a in Myocardial Hypertrophy Cell Cycle
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>史</surname><given-names>雪敏</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>佳靖</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吕</surname><given-names>佳玲</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>赵</surname><given-names>宇航</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>包钢集团公司劳动卫生职业病防治研究所，内蒙古 包头</addr-line></aff><aff id="aff2"><addr-line>包头医学院公共卫生学院，内蒙古 包头</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>03</day><month>07</month><year>2019</year></pub-date><volume>09</volume><issue>03</issue><fpage>128</fpage><lpage>134</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   心血管疾病严重威胁人类健康，其中心肌肥大和心肌纤维化是心血管疾病发展的主要表现。microRNA-29在心肌肥大和纤维化过程中都发生异常表达，并且参与纤维化、肿瘤增殖等过程。本研究通过建立肥大心肌细胞体外模型，研究miR-29a在心肌肥大过程中的变化水平及肥大心肌细胞细胞周期相关蛋白的表达模式变化。将常规培养H9C2心肌细胞系使用1 &#215; 10<sup>−5</sup>
   、1 &#215; 10
   <sup>−6</sup>
   和1 &#215; 1<sup>−7</sup>
   
    mol/L浓度的AngII诱导48 h后，检测细胞面积、细胞总蛋白含量，确定肥大心肌细胞诱导结果；再利用qPCR方法检测不同组的miR-29a、Cyclin A2、Bcl-2、Plk-1表达水平。结果显示使用浓度为1 &#215; 10<sup>−5</sup>、1 &#215; 10<sup>−6</sup>
   
    mol/L的AngII对H9C2诱导48 h后，细胞面积明显增大，细胞的总蛋白含量也增加，并且miR-29a表达水平显著升高；细胞周期相关的CyclinA2、Bcl-2和Plk-1在高浓度(1 &#215; 10
   <sup>−5</sup>
    mol/L) AngII诱导后表达水平上升，低浓度(1 &#215; 10
   <sup>−7</sup>
    mol/L) AngII诱导后表达水平下降。在肥大心肌模型建立过程中，miR-29a可能能够对细胞周期相关基因产生抑制。
    Cardiovascular disease is a serious threat to human health, among which myocardial hypertrophy and myocardial fibrosis are the main manifestations of the development of cardiovascular disease. microRNA-29 was abnormally expressed in the process of myocardial hypertrophy and fibrosis, and was involved in fibrosis, tumor proliferation and other processes. In this study, an 
   in vitro
    model of hypertrophic cardiomyocytes was established to study the changes of miR-29a in the process of cardiac hypertrophy and the changes of cell cycle related protein expression patterns in hypertrophic cardiomyocytes. H9C2 cardiomyocytes were induced with AngII at concentrations of 1 &#215; 10<sup>−5</sup>、1 &#215; 10<sup>−6</sup> and 1 &#215; 1<sup>−7</sup>
   
    mol/L for 48 h, the cell area and total protein content were detected. The expression levels of miR-29a, Cyclin A2, Bcl-2 and Plk-1 in different groups were detected by qPCR. The results showed that after 48 h of induction with a concentration of 1 &#215; 10<sup>−5</sup>
   
    and1 &#215; 10<sup>−6</sup>
   
    mol/L, the cell area increased significantly, the total protein content of the cells also increased, and the expression level of miR-29a was significantly increased. The expression levels of Cyclin A2, Bcl-2 and Plk-1 increased after AngII induction at high concentration (1 &#215; 10<sup>−5</sup>
   
    mol/L), while decreased after at low concentration (1 &#215; 1<sup>−7</sup>
   ). Mir-29a may inhibit cell cycle related genes during the establishment of hypertrophic myocardium model. 
  
 
</p></abstract><kwd-group><kwd>心肌肥大，细胞周期，miR-29a,  Cardiac Hypertrophy</kwd><kwd> Cell Cycle</kwd><kwd> miR-29a</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>microRNA-29a对肥大心肌细胞细胞周期的 影响研究<sup> </sup></title><p>史雪敏<sup>1</sup>，张佳靖<sup>2</sup>，吕佳玲<sup>1</sup>，赵宇航<sup>1*</sup></p><p><sup>1</sup>包头医学院公共卫生学院，内蒙古 包头</p><p><sup>2</sup>包钢集团公司劳动卫生职业病防治研究所，内蒙古 包头</p><disp-formula id="hanspub.31260-formula17"><graphic xlink:href="//html.hanspub.org/file/4-1530130x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2019年6月24日；录用日期：2019年7月8日；发布日期：2019年7月15日</p><disp-formula id="hanspub.31260-formula18"><graphic xlink:href="//html.hanspub.org/file/4-1530130x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>心血管疾病严重威胁人类健康，其中心肌肥大和心肌纤维化是心血管疾病发展的主要表现。microRNA-29在心肌肥大和纤维化过程中都发生异常表达，并且参与纤维化、肿瘤增殖等过程。本研究通过建立肥大心肌细胞体外模型，研究miR-29a在心肌肥大过程中的变化水平及肥大心肌细胞细胞周期相关蛋白的表达模式变化。将常规培养H9C2心肌细胞系使用1 &#215; 10<sup>−5</sup>、1 &#215; 10<sup>−6</sup>和1 &#215; 10<sup>−7</sup> mol/L浓度的AngII诱导48 h后，检测细胞面积、细胞总蛋白含量，确定肥大心肌细胞诱导结果；再利用qPCR方法检测不同组的miR-29a、Cyclin A2、Bcl-2、Plk-1表达水平。结果显示使用浓度为1 &#215; 10<sup>−5</sup>、1 &#215; 10<sup>−6</sup> mol/L的AngII对H9C2诱导48 h后，细胞面积明显增大，细胞的总蛋白含量也增加，并且miR-29a表达水平显著升高；细胞周期相关的CyclinA2、Bcl-2和Plk-1在高浓度(1 &#215; 10<sup>−5</sup> mol/L) AngII诱导后表达水平上升，低浓度(1 &#215; 10<sup>−7</sup> mol/L) AngII诱导后表达水平下降。在肥大心肌模型建立过程中，miR-29a可能能够对细胞周期相关基因产生抑制。</p><p>关键词 :心肌肥大，细胞周期，miR-29a</p><disp-formula id="hanspub.31260-formula19"><graphic xlink:href="//html.hanspub.org/file/4-1530130x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/4-1530130x8_hanspub.png" /> <img src="//html.hanspub.org/file/4-1530130x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 前言</title><p>心血管疾病患病人群逐年增加，不但严重威胁人群健康，而且严重消耗国家医疗资源，给家庭和社会造成沉重负担。心肌细胞肥大及纤维化是心血管疾病发展的主要病理表现，许多因素在这一病理过程中发挥不同作用。心肌肥大是许多心血管疾病共有的病理改变，是心脏对负荷增加、内分泌激活和能量代谢障碍体液因子改变、等多种刺激的一种适应性应答反应 [<xref ref-type="bibr" rid="hanspub.31260-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.31260-ref2">2</xref>]。早期的心肌肥大有利于维持正常的心脏功能，但这种代偿并非是良性的，越来越多的研究证明长期的应激最终会导致心律失常、心力衰竭、猝死，这说明心肌肥大是多种心血管事件的独立危险因素 [<xref ref-type="bibr" rid="hanspub.31260-ref3">3</xref>]。</p><p>microRNA是一种长度为22nt的短链RNA，能够通过调节基因表达来参与多种生命过程，包括早期发育，细胞增殖、凋亡和分化等。研究发现在心室重构、心力衰竭、心肌细胞凋亡等过程都受到miRNA的调控 [<xref ref-type="bibr" rid="hanspub.31260-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.31260-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.31260-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.31260-ref7">7</xref>]。目前证实在心脏重构/心衰过程中表达下调的miRNAs主要有miR-1、miR-133、miR-30、miR-29、miR-10、miR-19、miR-101等 [<xref ref-type="bibr" rid="hanspub.31260-ref8">8</xref>]。其中miR-29a可能参与心肌纤维化和心肌肥大的发生和发展。心肌梗死后心肌纤维化的形成伴随着miR-29a表达下调和Collagen 1A1基因表达增加 [<xref ref-type="bibr" rid="hanspub.31260-ref9">9</xref>] ，而且心肌肥大患者的血浆miR-29a表达水平上升，能够作为心肌肥大和纤维化的分子标志物 [<xref ref-type="bibr" rid="hanspub.31260-ref10">10</xref>]。同时，miR-29a还参与细胞周期的调节 [<xref ref-type="bibr" rid="hanspub.31260-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.31260-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.31260-ref13">13</xref>] ，但是目前仍未有研究阐明miR-29a如何调控心肌肥大及其表达变化是否能够影响心肌细胞周期。</p><p>本研究主要通过血管紧张素II构建H9C2体外肥大心肌细胞模型，比较正常心肌细胞和肥大心肌细胞中miR-29a、CyclinA2、Bcl-2、Plk-1的表达水平，确定肥大心肌细胞中miR-29a的表达变化和细胞周期的变化。</p></sec><sec id="s4"><title>2. 材料与方法</title><sec id="s4_1"><title>2.1. 材料与设备</title><sec id="s4_1_1"><title>2.1.1. 材料</title><p>大鼠心肌细胞系H9C2，购自武汉普诺赛生命科技有限公司。</p></sec><sec id="s4_1_2"><title>2.1.2. 主要设备</title><p>TE2000-U倒置显微镜(Nikon)；CO<sub>2</sub>培养箱(Thermo)；NanoDrop 2000微量分光光度计(Thermo)；PCR仪(Thermo)；Light Cycler<sup>&#174;</sup> 96 PCR仪(Roche)；高速低温离心机(Thermo)。</p></sec><sec id="s4_1_3"><title>2.1.3. 主要试剂</title><p>胰蛋白酶、DMEM培养基、胎牛血清(FBS)、磷酸盐缓冲液(PBS)均购于以色列Biological Industries公司；DMSO、血管紧张素(AngII)购于美国SIGMA公司，TransZolUP、细胞蛋白提取试剂盒、无酶水购于北京全式金公司；异丙醇，无水乙醇，氯仿均购于天津凯通化学试剂有限公司；GoScript<sup>TM</sup> Reverse Transcription System，Go Taq&#174; qPCR Master Mix购于普洛麦格(北京)生物技术有限公司；引物由上海生工生物技术有限公司合成，序列如表1所示。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Sequences of primers for qPC</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >基因名称</th><th align="center" valign="middle" >Forward Primer</th><th align="center" valign="middle" >Reverse Primer</th></tr></thead><tr><td align="center" valign="middle" >miR-29a</td><td align="center" valign="middle" >AGCACCACGAAACGG</td><td align="center" valign="middle" >—</td></tr><tr><td align="center" valign="middle" >U6</td><td align="center" valign="middle" >CTCGCTTCGGCAGCACATATACT</td><td align="center" valign="middle" >ACGCTTCACGAATTTGCGTGTC</td></tr><tr><td align="center" valign="middle" >GAPDH</td><td align="center" valign="middle" >TCGTGGAGTCTACTGGCGTCTT</td><td align="center" valign="middle" >CATTGCTGACAATCTTGAGGGAG</td></tr><tr><td align="center" valign="middle" >Cyclin A2</td><td align="center" valign="middle" >GTATTTGCCATCGCTTATTGCTG</td><td align="center" valign="middle" >CTGTGGTGCTTTGAGGTAGGTCTG</td></tr><tr><td align="center" valign="middle" >Bcl-2</td><td align="center" valign="middle" >CAGCGTCTGGAACAGTTGGTG</td><td align="center" valign="middle" >CGAGGGACTTGAGCAGTTTGG</td></tr><tr><td align="center" valign="middle" >Plk-1</td><td align="center" valign="middle" >GTCTGCCTATTACCTGCCTCACC</td><td align="center" valign="middle" >CACTCGATGGCCTCATTTGTCTC</td></tr></tbody></table></table-wrap><p>表1. qPCR引物序列</p></sec></sec><sec id="s4_2"><title>2.2. 方法</title><sec id="s4_2_1"><title>2.2.1. 细胞培养和肥大心肌细胞诱导</title><p>常规培养H9C2细胞。将常规传代的H9C2细胞以1 &#215; 10<sup>5</sup>个/孔的细胞数量接种于6孔板中，使用含10%胎牛血清的DMEM高糖培养液于37℃、5% CO<sub>2</sub>、饱和湿度培养箱中培养，待其生长至汇合度达到50%~70%后，添加终浓度为0、1 &#215; 10<sup>−5</sup> mol/L，1 &#215; 10<sup>−6</sup> mol/L，1 &#215; 10<sup>−7</sup> mol/L的AngII诱导48 h，分别记作CTRL、105、106、107组。</p><p>诱导48 h后，对各组细胞进行拍照，使用ImageJ软件对细胞进行面积测量，比较各组间细胞面积差异。再将细胞重悬后，计数相同数量的细胞，使用试剂盒提取细胞总蛋白，使用BAC法测定总蛋白量。</p></sec><sec id="s4_2_2"><title>2.2.2. 基因表达检测</title><p>使用全式金公司TransZol up总RNA提取试剂盒提取各组总RNA，分别按照反转录试剂盒说明书进行microRNA反转录和mRNA反转录，再使用qPCR技术检测各组miR-29a、Cyclin A2、Bcl-2、Plk-1相对表达量。</p></sec><sec id="s4_2_3"><title>2.2.3. 统计学分析</title><p>采用GraphPad Prism 8进行统计学分析，数据使用ANOVA法进行单因素方差分析，比较各组与CTRL间的均数标准差差异，p &lt; 0.05认为具有显著性差异。</p></sec></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 肥大心肌模型建立</title><p>正常H9C2心肌细胞呈梭形，折光性良好，细胞饱满；经过不同浓度AngII诱导48h后，细胞的表面积增加，向周围伸展较大，其中以1 &#215; 10<sup>−5</sup> mol/L浓度的AngII处理后的细胞体积最大。经过诱导后的细胞蛋白总量上升(图1，表2)。</p><p>图1. H9C2细胞经AngII诱导48 h后生长状态(200&#215;)</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Contrast of cell surface areas and total protein concentrations after AngII induced for 48 h ( x &#175; &#177; S </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >细胞表面积(Pixels)</th><th align="center" valign="middle" >细胞总蛋白量(mg/mL)</th></tr></thead><tr><td align="center" valign="middle" >CTRL</td><td align="center" valign="middle" >725.43 &#177; 250.47</td><td align="center" valign="middle" >1.28 &#177; 0.20</td></tr><tr><td align="center" valign="middle" >105</td><td align="center" valign="middle" >1686.09 &#177; 508.34<sup>*</sup></td><td align="center" valign="middle" >3.24 &#177; 0.44<sup>*</sup></td></tr><tr><td align="center" valign="middle" >106</td><td align="center" valign="middle" >1271.22 &#177; 284.96<sup>*</sup><sup> </sup></td><td align="center" valign="middle" >2.64 &#177; 0.37<sup>*</sup></td></tr><tr><td align="center" valign="middle" >107</td><td align="center" valign="middle" >712.91 &#177; 224.59</td><td align="center" valign="middle" >2.22 &#177; 0.35<sup>*</sup></td></tr></tbody></table></table-wrap><p>表2. 不同浓度AngII诱导48 h后H9C2细胞面积和蛋白总量比较( x &#175; &#177; S )</p><p>注：*与CTRL比较，p &lt; 0.05。</p></sec><sec id="s5_2"><title>3.2. miR-29a，CyclinA2，Bcl-2，Plk-1的表达</title><p>使用qPCR方法对miR-29a、Plk-1、Bcl-2和Cyclin A2的表达情况进行检测后发现(图2)，与CTRL组相比，在使用1 &#215; 10<sup>−5</sup> mol/L的AngII诱导后，miR-29a、Plk-1、Bcl-2和Cyclin A2的表达水平发生了显著上调；用1 &#215; 10<sup>−6</sup> mol/L的AngII诱导后miR-29a表达水平上升最高，Bcl-2、Cyclin A2表达水平也上升，但较105组低，而Plk-1表达水平下降；107组的miR-29a表达水平与CTRL没有差异，而Plk-1和Bcl-2的表达水平降低，Cyclin A2表达水平较CTRL略有升高。</p><p>图2. 不同处理组基因相对表达量变化</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>有研究证实miR-29a能够靶向Cyclin D2抑制细胞周期 [<xref ref-type="bibr" rid="hanspub.31260-ref14">14</xref>] ，而且低表达水平的miR-29a与肿瘤的增殖相关 [<xref ref-type="bibr" rid="hanspub.31260-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.31260-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.31260-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.31260-ref18">18</xref>] ，高表达miR-29a则可抑制肿瘤细胞的增殖。在肥厚型心肌病患者的外周血miRNAs中，miR-29a水平与心脏MRI显示的心肌肥厚及纤维化程度密切相关 [<xref ref-type="bibr" rid="hanspub.31260-ref10">10</xref>] ，它对心肌成纤维细胞的活化增殖起抑制作用，最终抑制纤维化的发生和发展 [<xref ref-type="bibr" rid="hanspub.31260-ref19">19</xref>] ，并且能够调节心肌细胞的代谢或引起心肌细胞的凋亡 [<xref ref-type="bibr" rid="hanspub.31260-ref20">20</xref>] ，抑制心肌肥大。本研究中使用AngII诱导H9C2细胞后，miR-29a表达水平显著上升，这与其他研究人员的发现类似，其高表达miR-29a后可能能够抑制正常心肌细胞向肥大心肌细胞转变。</p><p>Plk-1是存在于哺乳动物中的丝/苏氨酸激酶，位于细胞周期运行的中心环节，是调节细胞周期的重要分子 [<xref ref-type="bibr" rid="hanspub.31260-ref21">21</xref>]。Plk-1作为一种癌基因，在多种恶性肿瘤中高表达，参与了肿瘤的侵袭与转移 [<xref ref-type="bibr" rid="hanspub.31260-ref22">22</xref>] ，抑制Plk-1表达后，可导致多种肿瘤细胞生长的显著抑制和大规模细胞凋亡 [<xref ref-type="bibr" rid="hanspub.31260-ref23">23</xref>]。Plk-1表达水平在106组中下调，而105组中上调，这与肥大心肌细胞诱导后细胞活力下降相符。</p><p>Bcl-2是一种抗凋亡蛋白，对细胞凋亡有抑制作用 [<xref ref-type="bibr" rid="hanspub.31260-ref24">24</xref>]。miR-29可以直接靶向Bcl-2增加肝癌细胞(HCC)细胞对凋亡的敏感性，而且引入外源的miR-29到裸鼠体内，能够抑制肝癌细胞在裸鼠体内形成肿瘤的能力。这些研究结果表明，miR-29可通过抑制Bcl-2在线粒体通路促进细胞凋亡 [<xref ref-type="bibr" rid="hanspub.31260-ref25">25</xref>] [<xref ref-type="bibr" rid="hanspub.31260-ref26">26</xref>]。本研究中Bcl-2的表达量水平在10<sup>−5</sup> mol/L，10<sup>−6</sup> mol/L AngII诱导后的H9C2细胞中分别是空白对照组的3.30倍，1.60倍，表达量水平上调，但Bcl-2在高表达miR-29a组(106组)中的表达水平比低表达miR-29a组(105组)低，有可能miR-29a的高表达会导致Bcl-2的表达量下调，降低细胞活力。</p><p>Cyclin A2与有丝分裂紧密相关，它具有正性调节细胞周期活动的作用。Chaudhry H W等的研究中曾指出，哺乳动物心肌细胞的Cyclin A2在出生后不久便沉默，也就导致了成年哺乳动物心肌细胞几乎丧失了增殖能力 [<xref ref-type="bibr" rid="hanspub.31260-ref27">27</xref>]。但是最近不少相关研究表明成熟心肌细胞具有分裂增殖能力，可以重回细胞周期，分裂产生新细胞以适应负荷改变 [<xref ref-type="bibr" rid="hanspub.31260-ref28">28</xref>] [<xref ref-type="bibr" rid="hanspub.31260-ref29">29</xref>]。在研究心肌肥大机制时发现，在肥大初期Cyclin、CDK等细胞周期正性调节因子明显上调，CDKI等细胞周期负性调节因子明显下调 [<xref ref-type="bibr" rid="hanspub.31260-ref30">30</xref>]。在本研究中，10<sup>−5</sup> mol/L、10<sup>−6</sup> mol/L、10<sup>−7</sup> mol/L AngII对H9C2细胞诱导48h后，心肌细胞CyclinA2的表达量水平分别是空白对照组的5.82倍、2.25倍、1.29倍，可能是多种心肌肥大的信号机制共同调节，使得心肌细胞中CyclinA2的表达量水平上调，促进细胞增殖，以满足细胞肥大时对合成蛋白的需要。可以推测诱导时给予的AngII浓度越大，心肌细胞受到的刺激越强，增殖表达越强。</p><p>综上所述，心肌细胞在肥大初期，心肌细胞增殖在多种因素形成的复杂网络调控机制协同调控下，使得心肌细胞启动细胞分裂和增殖。与正常心肌细胞相比较，miR-29a、Bcl-2和Cyclin A2的表达水平都上调，并且高表达的miR-29a能够对细胞周期相关基因产生抑制，但尚不足以控制细胞的肥大变化，这需要进一步调控miR-29a后观察。同时miR-29a通过直接还是间接地靶向细胞周期相关基因调节心肌细胞的肥大变化还不清楚，也需要进一步的研究证实。</p></sec><sec id="s7"><title>基金项目</title><p>本研究受到内蒙古自然科学基金(2017BS0301)，内蒙古高等学校科研项目(NJZY17260)，包头医学院博士基金(BSJJ201608)和包头医学院杨帆计划(BYJJ-YF 201625)支持。</p></sec><sec id="s8"><title>文章引用</title><p>史雪敏,张佳靖,吕佳玲,赵宇航. microRNA-29a对肥大心肌细胞细胞周期的影响研究 Study of miR-29a in Myocardial Hypertrophy Cell Cycle[J]. 生物医学, 2019, 09(03): 128-134. https://doi.org/10.12677/HJBM.2019.93019</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.31260-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Shimizu, I. and Minamino, T. (2016) Physiological and Pathological Cardiac Hypertrophy. Journal of Molecular and Cellular Cardiology, 97, 245-262. &lt;br&gt;https://doi.org/10.1016/j.yjmcc.2016.06.001</mixed-citation></ref><ref id="hanspub.31260-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Tuomainen, T. and Tavi, P. (2017) The Role of Cardiac Energy Metabolism in Cardiac Hypertrophy and Failure. Experimental Cell Research, 360, 12-18. &lt;br&gt;https://doi.org/10.1016/j.yexcr.2017.03.052</mixed-citation></ref><ref id="hanspub.31260-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Berkin, K.E. and Ball, S.G. (2001) Essential Hypertension: The Heart and Hypertension. Heart, 86, 467-475.  
&lt;br&gt;https://doi.org/10.1136/heart.86.4.467</mixed-citation></ref><ref id="hanspub.31260-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Cordes, K.R. and Srivastava, D. (2009) MicroRNA Regulation of Cardiovascular Development. Circulation Research, 104, 724-732. &lt;br&gt;https://doi.org/10.1161/CIRCRESAHA.108.192872</mixed-citation></ref><ref id="hanspub.31260-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Thum, T., et al. (2007) MicroRNAs in the Human Heart: A Clue to Fetal Gene Reprogramming in Heart Failure. Circulation, 116, 258-267. &lt;br&gt;https://doi.org/10.1161/CIRCULATIONAHA.107.687947</mixed-citation></ref><ref id="hanspub.31260-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Van Rooij, E., et al. (2006) A Signature Pattern of Stress-Responsive microRNAs That Can Evoke Cardiac Hypertrophy and Heart Failure. Proceedings of the National Academy of Sciences of the United States of America, 103, 18255-18260. &lt;br&gt;https://doi.org/10.1073/pnas.0608791103</mixed-citation></ref><ref id="hanspub.31260-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Zuo, X., et al. (2012) Nicorandil Prevents Right Ventricular Re-modeling by Inhibiting Apoptosis and Lowering Pressure Overload in Rats with Pulmonary Arterial Hypertension. PLoS ONE, 7, e44485.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0044485</mixed-citation></ref><ref id="hanspub.31260-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Oliveiracarvalho, V., et al. (2013) MicroRNAs: New Players in Heart Failure. Molecular Biology Reports, 40, 2663- 2670. &lt;br&gt;https://doi.org/10.1007/s11033-012-2352-y</mixed-citation></ref><ref id="hanspub.31260-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Van Rooij, E., et al. (2008) Dysregulation of microRNAs after Myocardial Infarction Reveals a Role of miR-29 in Cardiac Fibrosis. Proceedings of the National Academy of Sciences of the United States of America, 105, 13027-13032.  
&lt;br&gt;https://doi.org/10.1073/pnas.0805038105</mixed-citation></ref><ref id="hanspub.31260-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Roncarati, R., et al. (2014) Circulating miR-29a, among Other Up-Regulated MicroRNAs, Is the Only Biomarker for Both Hypertrophy and Fibrosis in Patients with Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 63, 920-927. &lt;br&gt;https://doi.org/10.1016/j.jacc.2013.09.041</mixed-citation></ref><ref id="hanspub.31260-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Wu, Z., et al. (2013) The Inhibitory Role of Mir-29 in Growth of Breast Cancer Cells. Journal of Experimental &amp; Clinical Cancer Research, 32, 98. &lt;br&gt;https://doi.org/10.1186/1756-9966-32-98</mixed-citation></ref><ref id="hanspub.31260-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Y., et al. (2013) The Role of miRNA-29 Family in Cancer. European Journal of Cell Biology, 92, 123-128.  
&lt;br&gt;https://doi.org/10.1016/j.ejcb.2012.11.004</mixed-citation></ref><ref id="hanspub.31260-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Cui, Y., et al. (2011) MiR-29a Inhibits Cell Proliferation and In-duces Cell Cycle Arrest through the Downregulation of p42.3 in Human Gastric Cancer. PLoS ONE, 6, e25872. &lt;br&gt;https://doi.org/10.1371/journal.pone.0025872</mixed-citation></ref><ref id="hanspub.31260-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">宋洋柳. GATA4招募PCG蛋白介导miR-29a表达调控C2C12细胞增殖与分化的机制研究[D]: [硕士学位论文]. 郑州: 郑州大学, 2016.</mixed-citation></ref><ref id="hanspub.31260-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">招霞. PTEN-PI3K-PDK1-Akt信号通路对心脏发育和心脏功能作用的研究[D]: [博士学位论文]. 南京: 南京大学, 2012.</mixed-citation></ref><ref id="hanspub.31260-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">王晓. microRNA-29a在肝癌患者中的表达及对肝癌细胞增殖、迁移能力的研究[D]: [博士学位论文]. 郑州: 郑州大学, 2017.</mixed-citation></ref><ref id="hanspub.31260-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">王慧玲, 等. miR-29a调控HDAC4促肝癌细胞增殖和转移的机制研究[J]. 胃肠病学和肝病学杂志, 2017, 26(4): 381-385.</mixed-citation></ref><ref id="hanspub.31260-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">王慧玲, 等. miR-29a调控IRS1促进肝门部胆管癌细胞增殖的机制研究[J]. 胃肠病学和肝病学杂志, 2019, 28(4): 456-460.</mixed-citation></ref><ref id="hanspub.31260-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Ramdas, V., et al. (2013) Canonical Transforming Growth Factor-Beta Signaling Regulates Disintegrin Metalloprotease Expression in Experimental Renal Fibrosis via miR-29. The American Journal of Pathology, 183, 1885-1896.  
&lt;br&gt;https://doi.org/10.1016/j.ajpath.2013.08.027</mixed-citation></ref><ref id="hanspub.31260-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">李晓, 等. miR-29a调控心肌肥大的分子机制研究[J]. 现代中西医结合杂志, 2017, 26(13): 1379-1381+1385.</mixed-citation></ref><ref id="hanspub.31260-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Yuan, J., et al. (2011) Polo-Box Domain Inhibitor Poloxin Ac-tivates the Spindle Assembly Checkpoint and Inhibits Tumor Growth in Vivo. The American Journal of Pathology, 179, 2091-2099.  
&lt;br&gt;https://doi.org/10.1016/j.ajpath.2011.06.031</mixed-citation></ref><ref id="hanspub.31260-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Kobayashi, Y., et al. (2015) Phase I Trial of Volasertib, a Po-lo-Like Kinase Inhibitor, in Japanese Patients with Acute Myeloid Leukemia. Cancer Science, 106, 1590-1595. &lt;br&gt;https://doi.org/10.1111/cas.12814</mixed-citation></ref><ref id="hanspub.31260-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Harris, P.S., et al. (2012) Polo-Like Kinase 1 (PLK1) Inhibition Suppresses Cell Growth and Enhances Radiation Sensitivity in Medulloblastoma Cells. BMC Cancer, 12, 80. &lt;br&gt;https://doi.org/10.1186/1471-2407-12-80</mixed-citation></ref><ref id="hanspub.31260-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, N., et al. (2016) Cardiac Ankyrin Repeat Protein Attenuates Cardiomyocyte Apoptosis by Upregulation of Bcl-2 Expression. Biochimica et Biophysica Acta, 1863, 3040-3049. &lt;br&gt;https://doi.org/10.1016/j.bbamcr.2016.09.024</mixed-citation></ref><ref id="hanspub.31260-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Xiong, Y., et al. (2010) Effects of microRNA-29 on Apoptosis, Tumorigenicity, and Prognosis of Hepatocellular Carcinoma. Hepatology, 51, 836-845. &lt;br&gt;https://doi.org/10.1002/hep.23380</mixed-citation></ref><ref id="hanspub.31260-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Jafarinejad-Farsangi, S., et al. (2015) MicroRNA-29a Induces Apoptosis via Increasing the Bax:Bcl-2 Ratio in Dermal Fibroblasts of Patients with Systemic Sclerosis. Autoimmunity, 48, 369-378.  
&lt;br&gt;https://doi.org/10.3109/08916934.2015.1030616</mixed-citation></ref><ref id="hanspub.31260-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Chaudhry, H.W., et al. (2004) Cyclin A2 Mediates Cardiomyocyte Mitosis in the Postmitotic Myocardium. The Journal of Biological Chemistry, 279, 35858-35866. &lt;br&gt;https://doi.org/10.1074/jbc.M404975200</mixed-citation></ref><ref id="hanspub.31260-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Anversa, P. and Kajstura, J. (1998) Ventricular Myocytes Are Not Terminally Differentiated in the Adult Mammalian Heart. Circulation Research, 83, 1-14. &lt;br&gt;https://doi.org/10.1161/01.RES.83.1.1</mixed-citation></ref><ref id="hanspub.31260-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Beltrami, A.P., et al. (2001) Evidence That Human Cardiac Myocytes Divide after Myocardial Infarction. The New England Journal of Medicine, 344, 1750-1757. &lt;br&gt;https://doi.org/10.1056/NEJM200106073442303</mixed-citation></ref><ref id="hanspub.31260-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Brooks, G., et al. (1997) Expression and Activities of Cy-clins and Cyclin-Dependent Kinases in Developing Rat Ventricular Myocytes. Journal of Molecular and Cellular Car-diology, 29, 2261-2271.  
&lt;br&gt;https://doi.org/10.1006/jmcc.1997.0471</mixed-citation></ref></ref-list></back></article>